Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.66 EUR
Change Today +0.023 / 3.63%
Volume 0.0
HG6 On Other Exchanges
As of 2:11 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

mayne pharma group ltd (HG6) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/15 - €0.87
52 Week Low
12/15/14 - €0.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MAYNE PHARMA GROUP LTD (HG6)

Related News

No related news articles were found.

mayne pharma group ltd (HG6) Related Businessweek News

No Related Businessweek News Found

mayne pharma group ltd (HG6) Details

Mayne Pharma Group Limited, a specialty pharmaceutical company, develops, manufactures, and distributes branded and generic products worldwide. It operates through three segments: Mayne Pharma International, US Products, and Metrics Contract Services. The company’s branded products comprise Doryx capsules to treat severe acne and as an anti-malarial; ESGIC tablets and capsules to treat tension headaches; ZEBUTAL capsules for treating tension headaches; LORCET tablets; Eryc/Erymax capsules for treating bacterial infections; Kapanol/Kadian capsules for managing moderate to severe chronic pain; Lozanoc/Itragerm capsules for treating fungal infections; and Urocarb tablets. Its generic products include Amiodarone HCl tablets for recurrent ventricular arrhythmias; Bromfenac sodium solution for treating postoperative inflammation and reducing ocular pain; Butalbital/APAP/caffeine capsules; Doxycycline hyclate tablets to treat infections; Erythromycin capsules for bacterial infections; Hydrocodone/APAP, Oxycodone HCl, and Oxycodone/APAP tablets for moderate to severe pain; Liothyronine sodium tablets to treat hypothyroidism; Methamphetamine tablets for attention deficit disorder treatment; Nystatin topical powder to treat fungal infections; and Doxorubicin, Irinotecan, Methotrexate, Midazolam, Ondansetron, and Oxaliplatin for injection. The company also offers OTC/pharmacy products, such as Astrix capsules and tablets; Licener for children suffering from head lice; Magnoplasm paste; Percutane pain relief and sports creams; Doxycycline capsules; Aspirin tablets; and Erythromycin capsules, as well as contract development and manufacturing services. It sells its products directly or through distribution partners, as well as operates an online store. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Salisbury South, Australia.

600 Employees
Last Reported Date: 08/27/15

mayne pharma group ltd (HG6) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$626.7K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$345.5K
Vice President of Operations
Total Annual Compensation: A$89.3K
President of Mayne Pharma USA
Total Annual Compensation: A$461.4K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: A$298.4K
Compensation as of Fiscal Year 2015.

mayne pharma group ltd (HG6) Key Developments

Mayne Pharma Group Ltd to Expand Manufacturing Capacity in US

Mayne Pharma Group Ltd. announced that the company will make a $65 million expansion of its operations in Greenville, NC, USA to support projected growth of US products and metrics contract services. The investment will fund a new Greenfield 126,000 sqft oral-dose commercial manufacturing facility on land owned by the company and adjacent to its existing facility. The investment will more than double US manufacturing capacity plus repurpose existing space to significantly expand contract analytical and formulation development services capacity.

Mayne Pharma Group Limited Announces Unaudited Consolidated Earnings Results for the Year Ended June 30, 2015

Mayne Pharma Group Limited announced unaudited consolidated earnings results for the year ended June 30, 2015. For the year, the company reported revenue of AUD 141,420,000, profit before income tax of AUD 11,243,000, net profit from continuing operations after income tax of AUD 7,537,000, net profit attributable to equity holders of the parent of AUD 7,759,000 or 1.15 cents per diluted share, net cash flows from operating activities of AUD 22,420,000, payments for property, plant and equipment of AUD 4,174,000, payments for intangible assets of AUD 65,917,000, payments for capitalised development costs of AUD 13,512,000 compared to the revenue of AUD 143,254,000, profit before income tax of AUD 28,022,000, net profit from continuing operations after income tax of AUD 21,290,000, net profit attributable to equity holders of the parent of AUD 21,290,000 or 3.6 cents per diluted share, net cash flows from operating activities of AUD 26,136,000, payments for property, plant and equipment of AUD 4,203,000, payments for intangible assets of AUD 11,439,000, payments for capitalised development costs of AUD 16,279,000 for the previous year The impact on the Group’s profit before tax is due to changes in the fair value of monetary assets and liabilities including non- designated foreign currency derivatives and embedded derivatives. The pre-tax impact on the Group’s equity is due to changes in the fair value of forward exchange contracts designated as cash flow hedges and net investment hedges. Adjusted EBITDA was AUD 36.4 million against AUD 40.4 million a year ago. EBITDA was AUD 36.4 million against AUD 40.4 million a year ago.

Mayne Pharma Group Limited Announces Executive Changes

Mayne Pharma Group Limited announce two additions to its executive leadership team. Mr. Peter Paltoglou will be joining the Company as Executive Vice President (EVP) of Corporate and Business Development with global responsibility for M&A, strategic planning, licensing arrangements and third party partnerships. Mr. Paltoglou is an accomplished M&A executive with over 15 years' of experience in executing public and private mergers and acquisitions, capital management and corporate strategy across a range of market sectors. He was previously Managing Director of Investment Banking at Credit Suisse Emerging Companies in Australia where he advised Mayne Pharma on the transformational acquisitions of Metrics and Doryx, the recently completed debt refinancing and a number of other material enterprise and product deals. Prior to Credit Suisse, Mr. Paltoglou was a Director of Hindal Group, a boutique M&A advisory business. Mr. Eric Evans has been appointed to the role of Chief Financial Officer (CFO) of Mayne Pharma USA. Mr. Evans brings to Mayne Pharma more than 30 years' of experience in financial leadership roles across both the pharmaceutical and contract services sectors. He was previously the CFO of AAIPharma Services, a leading global provider of contract services with over 800 employees across seven sites in the US and Europe. Prior to AAIPharma, he was CFO and EVP at Patheon Inc. and VP and controller for Novartis Pharmaceuticals US branded business with sales in excess of US$8 billion. He was also CFO for Sandoz US, one of the generic pharma companies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HG6:GR €0.66 EUR +0.023

HG6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HG6.
View Industry Companies

Industry Analysis


Industry Average

Valuation HG6 Industry Range
Price/Earnings 84.8x
Price/Sales 5.0x
Price/Book 2.5x
Price/Cash Flow 47.1x
TEV/Sales 4.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAYNE PHARMA GROUP LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at